To evaluate the potential for applying GMP-ready robotic systems to commercial-scale cell therapy manufacturing.

Biomanufacturing company Multiply Labs is using Nvidia technologies to develop robotic biomanufacturing systems for ...

Multiply Labs' goal is to enable scalable, high-throughput manufacturing while maintaining rigorous quality and regulatory standards.

Multiply Labs is developing robotics-first biomanufacturing systems intended to bring greater consistency, traceability, and operational efficiency to advanced therapy production-so personalized ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced performance results for ...

Breakthrough partnership with Universal Robots transforms "artisanal" manufacturing, making personalized, life-saving cancer treatments affordable and widely available. "Historically, cell and gene ...

By utilizing Multiply Labs' cell therapy robotic cluster and GenScript's GMP-grade CytoSinct 1000 cell isolation solution, capable of isolating up to 120X10^9 total cells within a single hour, this ...

Multiply Labs, a San Francisco-based robotics company developing advanced automated manufacturing systems for cell therapies, announced an expansion of its collaboration with Thermo Fisher Scientific.

Multiply Labs, a robotics firm, and Retro Biosciences, which is developing therapies to address age-related diseases, signed an agreement valued at up to $85 million to automate Retro’s approach to ...